Market Place
Sourcing Support
Venetoclax Plus Obinutuzumab Demonstrates Durable Survival Benefit
22 Jun 2023 //
PRESS RELAESE
Chugai Pharma’s Gazyva gets Japanese MHLW approval for an additional indication
24 Dec 2022 //
PHARMABIZ
J&J gets EMA backing for Imbruvica-venetoclax combination
29 Jun 2022 //
FIERCEPHARMA
TG Therapeutics Falls 30% As CEO Discloses Partial Clinical Hold
28 Jan 2022 //
YAHOO FINANCE
First-Line Ibrutinib/Venetoclax Better Than Chlorambucil/Obinutuzumab
18 Jun 2021 //
CANCERTHERAPYADVISOR
IMBRUVICA Plus VENCLEXTA/VENCLYXTO (venetoclax) Combination Positive Results
14 Jun 2021 //
PRESS RELEASE
First-Line Ibrutinib + Venetoclax Is Superior to Chlorambucil + Obinutuzumab
12 Jun 2021 //
PRNEWSWIRE
TG`s leukemia combo clears phase 3, aims for 2020 filing
05 May 2020 //
FIERCE BIOTECH
FDA lifts hold on AbbVie, Roche`s Venclexta in myeloma
25 Jun 2019 //
FIERCE PHARMA
AstraZeneca`s Calquence sets Imbruvica in its sights
17 Jun 2019 //
FIERCE PHARMA
AstraZeneca`s Calquence treads on Imbruvica`s turf with second phase 3 CLL win
07 Jun 2019 //
FIERCE PHARMA
AbbVie unveils Venclexta data
04 Jun 2019 //
FIERCE PHARMA
Roche announces positive results from Gazyva/Gazyvaro phase 3 study
05 Dec 2016 //
PHARMABIZ
Italian pharma scandals prompts call for EU-wide pricing probe
19 Oct 2016 //
PMLIVE
AbbVie, J&J leukemia drug cuts death risk vs chemo in new patients: study
08 Dec 2015 //
REUTERS
AbbVie`s Imbruvica, Amgen`s Kyprolis shine at annual ASH meeting
07 Dec 2015 //
FIERCE PHARMA MARKETING
Attix Pharmaceuticals Recalls Hundreds of APIs From the U.S.
02 May 2015 //
FIERCE PHARMA MFG
Novartis` Arzerra Shows Benefit in Relapsed CLL
27 Apr 2015 //
PHARMATIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.